MF59-adjuvanted vaccine: A safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

Paolo Durando, Giancarlo Icardi, Filippo Ansaldi

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Importance of the field: Vaccination is universally considered as the most effective tool for the prevention of influenza, which represents a significant burden, both from a health-care and a socio-economic viewpoint. Conventional non-adjuvanted vaccines have shown suboptimal immunogenicity in the elderly, in patients with serious chronic diseases or the immunocompromised and in young children. The protection offered by non-adjuvanted vaccines may be further reduced by periodic antigenic drifts. Areas covered in this review: Between the several strategies proposed to address the need for more immunogenic vaccines than the conventional ones, the most successful strategy is represented by the use of adjuvants. Since 1997, an MF59-adjuvanted subunit influenza vaccine has been licensed in several countries and used in the elderly worldwide. Available data on the safety, immunogenicity and effectiveness of this vaccine have been reported and discussed in details. What the reader will gain: The MF59-adjuvanted vaccine has been shown to enhance immunogenicity and to confer cross-reactivity against heterologous influenza viral strains in the elderly, in adults with serious underlying medical conditions and in healthy infants and young children. Furthermore, its effectiveness has been demonstrated in older adults, reducing hospitalizations for pneumonia, cardiovascular and cerebrovascular diseases. Take home message: The vaccine is safe, with an acceptable tolerability profile, thus representing a valid option to optimize the control of seasonal influenza.

Original languageEnglish
Pages (from-to)639-651
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Orthomyxoviridae
Viruses
Vaccines
Human Influenza
Cerebrovascular Disorders
Subunit Vaccines
Influenza Vaccines
Pneumonia
Health care
Vaccination
Hospitalization
Chronic Disease
Cardiovascular Diseases
Economics
MF59 oil emulsion
Delivery of Health Care
Safety

Keywords

  • Cross-reactivity
  • Immunogenicity
  • Influenza vaccines
  • MF59 adjuvant
  • Safety

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Drug Discovery
  • Pharmacology

Cite this

MF59-adjuvanted vaccine : A safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. / Durando, Paolo; Icardi, Giancarlo; Ansaldi, Filippo.

In: Expert Opinion on Biological Therapy, Vol. 10, No. 4, 04.2010, p. 639-651.

Research output: Contribution to journalArticle

@article{a4ffa72fc1214a6ea57c9362e447b1e6,
title = "MF59-adjuvanted vaccine: A safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk",
abstract = "Importance of the field: Vaccination is universally considered as the most effective tool for the prevention of influenza, which represents a significant burden, both from a health-care and a socio-economic viewpoint. Conventional non-adjuvanted vaccines have shown suboptimal immunogenicity in the elderly, in patients with serious chronic diseases or the immunocompromised and in young children. The protection offered by non-adjuvanted vaccines may be further reduced by periodic antigenic drifts. Areas covered in this review: Between the several strategies proposed to address the need for more immunogenic vaccines than the conventional ones, the most successful strategy is represented by the use of adjuvants. Since 1997, an MF59-adjuvanted subunit influenza vaccine has been licensed in several countries and used in the elderly worldwide. Available data on the safety, immunogenicity and effectiveness of this vaccine have been reported and discussed in details. What the reader will gain: The MF59-adjuvanted vaccine has been shown to enhance immunogenicity and to confer cross-reactivity against heterologous influenza viral strains in the elderly, in adults with serious underlying medical conditions and in healthy infants and young children. Furthermore, its effectiveness has been demonstrated in older adults, reducing hospitalizations for pneumonia, cardiovascular and cerebrovascular diseases. Take home message: The vaccine is safe, with an acceptable tolerability profile, thus representing a valid option to optimize the control of seasonal influenza.",
keywords = "Cross-reactivity, Immunogenicity, Influenza vaccines, MF59 adjuvant, Safety",
author = "Paolo Durando and Giancarlo Icardi and Filippo Ansaldi",
year = "2010",
month = "4",
doi = "10.1517/14712591003724662",
language = "English",
volume = "10",
pages = "639--651",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - MF59-adjuvanted vaccine

T2 - A safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

AU - Durando, Paolo

AU - Icardi, Giancarlo

AU - Ansaldi, Filippo

PY - 2010/4

Y1 - 2010/4

N2 - Importance of the field: Vaccination is universally considered as the most effective tool for the prevention of influenza, which represents a significant burden, both from a health-care and a socio-economic viewpoint. Conventional non-adjuvanted vaccines have shown suboptimal immunogenicity in the elderly, in patients with serious chronic diseases or the immunocompromised and in young children. The protection offered by non-adjuvanted vaccines may be further reduced by periodic antigenic drifts. Areas covered in this review: Between the several strategies proposed to address the need for more immunogenic vaccines than the conventional ones, the most successful strategy is represented by the use of adjuvants. Since 1997, an MF59-adjuvanted subunit influenza vaccine has been licensed in several countries and used in the elderly worldwide. Available data on the safety, immunogenicity and effectiveness of this vaccine have been reported and discussed in details. What the reader will gain: The MF59-adjuvanted vaccine has been shown to enhance immunogenicity and to confer cross-reactivity against heterologous influenza viral strains in the elderly, in adults with serious underlying medical conditions and in healthy infants and young children. Furthermore, its effectiveness has been demonstrated in older adults, reducing hospitalizations for pneumonia, cardiovascular and cerebrovascular diseases. Take home message: The vaccine is safe, with an acceptable tolerability profile, thus representing a valid option to optimize the control of seasonal influenza.

AB - Importance of the field: Vaccination is universally considered as the most effective tool for the prevention of influenza, which represents a significant burden, both from a health-care and a socio-economic viewpoint. Conventional non-adjuvanted vaccines have shown suboptimal immunogenicity in the elderly, in patients with serious chronic diseases or the immunocompromised and in young children. The protection offered by non-adjuvanted vaccines may be further reduced by periodic antigenic drifts. Areas covered in this review: Between the several strategies proposed to address the need for more immunogenic vaccines than the conventional ones, the most successful strategy is represented by the use of adjuvants. Since 1997, an MF59-adjuvanted subunit influenza vaccine has been licensed in several countries and used in the elderly worldwide. Available data on the safety, immunogenicity and effectiveness of this vaccine have been reported and discussed in details. What the reader will gain: The MF59-adjuvanted vaccine has been shown to enhance immunogenicity and to confer cross-reactivity against heterologous influenza viral strains in the elderly, in adults with serious underlying medical conditions and in healthy infants and young children. Furthermore, its effectiveness has been demonstrated in older adults, reducing hospitalizations for pneumonia, cardiovascular and cerebrovascular diseases. Take home message: The vaccine is safe, with an acceptable tolerability profile, thus representing a valid option to optimize the control of seasonal influenza.

KW - Cross-reactivity

KW - Immunogenicity

KW - Influenza vaccines

KW - MF59 adjuvant

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=77949430350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949430350&partnerID=8YFLogxK

U2 - 10.1517/14712591003724662

DO - 10.1517/14712591003724662

M3 - Article

C2 - 20218923

AN - SCOPUS:77949430350

VL - 10

SP - 639

EP - 651

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 4

ER -